These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2830367)

  • 1. ESR studies of molecular interactions of copper(II) nirvanol and copper(II) diisopropylsalicylate with Ehrlich ascites tumor cells.
    Pezeshk A; Antholine WE; Petering DH
    J Inorg Biochem; 1987 Dec; 31(4):283-91. PubMed ID: 2830367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESR studies of the interaction of copper(II)GHK, histidine, and Ehrlich cells.
    Antholine WE; Petering DH; Pickart L
    J Inorg Biochem; 1989 Mar; 35(3):215-24. PubMed ID: 2542448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial reaction of 3-ethyoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) copper(II) with Ehrlich ascites tumor cells.
    Minkel DT; Petering DH
    Cancer Res; 1978 Jan; 38(1):117-23. PubMed ID: 201367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells.
    Minkel DT; Saryan LA; Petering DH
    Cancer Res; 1978 Jan; 38(1):124-9. PubMed ID: 563285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-metal interactions: spectroscopic studies of copper hydantoin complexes.
    Pezeshk A; Pezeshk V
    J Inorg Biochem; 1991 Jun; 42(4):267-72. PubMed ID: 1652621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of 2-formylpyridine thiosemicarbazonato copper (II) with Ehrlich ascites tumor cells.
    Saryan LA; Mailer K; Krishnamurti C; Antholine W; Petering DH
    Biochem Pharmacol; 1981 Jun; 30(12):1595-604. PubMed ID: 7271847
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhancement of cytotoxicity of bleomycin by dithiocarbamates: formation of bis(dithiocarbamato) cu(II).
    Ujjani B; Lyman S; Winkelmann D; Antholine W; Petering DH; Jones MM
    J Inorg Biochem; 1990 Jan; 38(1):81-93. PubMed ID: 1692085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper(II)- and iron(II)-complexes of methyl 2-(2-aminoethyl)-aminomethyl-pyridine-6-carboxyl-histidinate (AMPHIS), a peptide mimicking the metal-chelating moiety of bleomycin. An ESR investigation.
    Hénichart JP; Bernier JL; Houssin R; Lohez M; Kenani A; Catteau JP
    Biochem Biophys Res Commun; 1985 Feb; 126(3):1036-41. PubMed ID: 2579645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antitumor activity of ascorbate against Ehrlich ascites tumor cells by the copper:glycylglycylhistidine complex.
    Kimoto E; Tanaka H; Gyotoku J; Morishige F; Pauling L
    Cancer Res; 1983 Feb; 43(2):824-8. PubMed ID: 6293704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidation-reduction reactions in Ehrlich cells treated with copper-neocuproine.
    Byrnes RW; Antholine WE; Petering DH
    Free Radic Biol Med; 1992 Nov; 13(5):469-78. PubMed ID: 1334027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and biological studies on Co(II), Ni(II) and Cu(II) complexes of carbohydrazones ending by pyridyl ring.
    Abu El-Reash GM; El-Gammal OA; Ghazy SE; Radwan AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2013 Mar; 104():26-34. PubMed ID: 23274253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proposed mode of action of antitumor platinum compounds based upon studies with cis-dichloro-((G- 3 H)dipyridine)platinum(II).
    Howle JA; Gale GR; Smith AB
    Biochem Pharmacol; 1972 May; 21(10):1465-75. PubMed ID: 5029426
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo and in vitro evaluation of highly specific thiolate carrier group copper(II) and zinc(II) complexes on Ehrlich ascites carcinoma tumor model.
    Raman N; Jeyamurugan R; Senthilkumar R; Rajkapoor B; Franzblau SG
    Eur J Med Chem; 2010 Nov; 45(11):5438-51. PubMed ID: 20864225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo anti-proliferative evaluation of bis(4'-(4-tolyl)-2,2':6',2″-terpyridine)copper(II) complex against Ehrlich ascites carcinoma tumors.
    Mahendiran D; Kumar RS; Viswanathan V; Velmurugan D; Rahiman AK
    J Biol Inorg Chem; 2017 Oct; 22(7):1109-1122. PubMed ID: 28884428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of the cytotoxicity of substituted [phenylglyoxal bis(4-methyl-3-thiosemicarbazone)] copper(II) chelates. 2. Parabolic correlations and their implications for selective toxicity.
    Coats EA; Milstein SR; Pleiss MA; Roesener JA
    J Med Chem; 1978 Aug; 21(8):804-9. PubMed ID: 691005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paramagnetic species in the plasma of dogs with lymphoma prior to and after treatment with doxorubicin. An ESR study.
    Gille L; Kleiter M; Willmann M; Nohl H
    Biochem Pharmacol; 2002 Dec; 64(12):1737-44. PubMed ID: 12445862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, structure, electrochemistry and spectral characterization of (D-glucopyranose)-4-phenylthiosemicarbazide metal complexes and their antitumor activity against Ehrlich ascites carcinoma in Swiss albino mice.
    Sathisha MP; Budagumpi S; Kulkarni NV; Kurdekar GS; Revankar VK; Pai KS
    Eur J Med Chem; 2010 Jan; 45(1):106-13. PubMed ID: 19854545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo Anticancer Effects of a Novel 9-Phenyldibenzo[a,c]phenazin-9-ium Cation and Its Ligands.
    Das S; Banerjee K; Biswas MK; Bhadra R; Ghosh P; Choudhuri SK
    Chemotherapy; 2014; 60(4):261-6. PubMed ID: 25926067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of 1,10-phenanthroline and its copper complex with Ehrlich cells.
    Byrnes RW; Antholine WE; Petering DH
    Free Radic Biol Med; 1992; 12(6):457-69. PubMed ID: 1318248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolism of 3-methyl-5-ethyl-5-phenylhydantoin (mephenytoin) to 5-ethyl-5-phenylhydantoin (Nirvanol) in mice in relation to anticonvulsant activity.
    Kupferberg HJ; Yonekawa W
    Drug Metab Dispos; 1975; 3(1):26-9. PubMed ID: 234831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.